Printer Friendly
The Free Library
19,604,530 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

DiaSys Reports Stock Purchase Agreement To Retire Convertible Preferred Stock and Cancel Approximately 550,000 Warrants.


Business/Medical Editors

WATERBURY, Conn.--(BW HealthWire)--April 4, 2002

DiaSys Corporation (AMEX AMEX

See: American Stock Exchange
: DYX DYX Dyslexia ) today announced that a group of purchasers, comprised mainly of its Officers and Directors, has entered into a stock purchase agreement (Agreement) with BH Capital and Excalibur Partners, holders of the Company's Convertible Preferred shares Preferred shares

Preferred shares give investors a fixed dividend from the company's earnings and entitle them to be paid before common shareholders. See: Preferred stock.
, to retire all of the Convertible Preferred and underlying common shares for $1.5 million.

Under the Agreement, BH and Excalibur also waived their right to receive additional warrants to purchase shares of the Company's common stock, and have forfeited any existing such warrants. The parties expect to complete all such transactions on or before April 8, 2002.

Todd M. DeMatteo, the Company's President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  said: "The existence of the Convertible Preferred has caused uncertainty as to the dilutive effect Dilutive effect

Result of a transaction that decreases earnings per common share (EPS).
 of shares on the market at any given time. Today's announcement ends this uncertainty." He said: "The Company also benefits from the anti-dilutive effect of removing some 550,000 warrants from circulation." Mr. DeMatteo added: "This transaction has strengthened our strategic growth program."

About DiaSys Corporation

DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and test kits to healthcare laboratories worldwide. The Company is headquartered in Waterbury, CT. It operates in Europe through its wholly owned subsidiary Wholly Owned Subsidiary

A subsidiary whose parent company owns 100% of its common stock.

Notes:
In other words, the parent company owns the company outright and there are no minority owners.
 based in Wokingham, England; and, in Pacific Asia through its strategic business partner located in Guangzhou China. DiaSys is a registered trademark of DiaSys Corporation.

The foregoing press release includes "forward looking statements" within the meaning of, and made pursuant to, the safe harbor provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 4, 2002
Words:340
Previous Article:TCP Stock Exchange Message.
Next Article:Stull, Stull & Brody Announces Class Action Lawsuit Against Adelphia Communications Corporation.
Topics:



Related Articles
Alliance Imaging announces 21 percent equity stake taken by General Electric; GE converts bridge loan into convertible preferred stock.
Bio-Plexus Announces New Terms and Year-End Results.
The Fortress Group Announces Restructuring of Prometheus Investment.
Bio-Plexus Reports Year-End Results.
DiaSys Announces $20 Million Letter of Commitment From BH Capital, an Affiliate of Reichmann International for Mergers, Acquisitions and Corporate...
Primedex Health Systems Inc. Reports Cancellation of Outstanding Preferred Stock.
DiaSys Reports End Of Its Convertible Preferred Stock.
Centiv Completes $2.5 Million Private Equity Financing; Capital Structure Significantly Improved.
Cambridge Heart Announces up to $6.5 Million in Equity Financing.
SpectRx, Inc. Completes $7.3 Million Private Placement.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles